Drug intelligence / Profile preview

trans sodium crocetinate + temozolomide + radiation therapy

Development stage
Discontinued
Lead developer
CervoMed
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

Trans sodium crocetinate (TSC) is a first-in-class small molecule oxygen diffusion-enhancing compound developed by Diffusion Pharmaceuticals. It is designed to increase the delivery of oxygen to hypoxic (oxygen-deprived) tissues by enhancing the diffusion of oxygen through blood plasma. In the treatment of glioblastoma multiforme (GBM), TSC is used as a radiosensitizer to improve the effectiveness of radiation therapy, as hypoxic tumor cells are typically resistant to radiation. The drug is administered intravenously in combination with the standard of care (SOC), which consists of temozolomide chemotherapy and radiation therapy. This combination was evaluated in the Phase 3 INTACT registration trial specifically for patients with newly diagnosed, inoperable (biopsy-only) glioblastoma.

Other names
transcrocetinate sodiumsodium trans-crocetinate
02

Targets

DNA

Beyond the preview

Go deeper on trans sodium crocetinate + temozolomide + radiation therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trans sodium crocetinate + temozolomide + radiation therapy.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call